October 1, 2020

Tmunity to Present at Upcoming Investor Conferences

PHILADELPHIA--(BUSINESS WIRE)--Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T-cell immunotherapy, today announced that President & CEO Usman “Oz” Azam is scheduled to present at two upcoming virtual investor conferences.​


Chardan 4th Annual Genetic Medicines Conference

Date: Monday, October 5, 2020

Time: 1:30 pm ET

Location: Presentation will be via webcast

Alliance of Regenerative Medicine 2020 Virtual Cell & Gene Meeting on the Mesa

Date: Monday, October 12 – Friday, October 16

Time: Company presentations will be available to view on-demand throughout the entirety of the conference

Location: Please visit www.meetingonthemesa.com for full information including registration.

​About Tmunity Therapeutics

Tmunity is a private, clinical-stage biotherapeutics company, focused on saving and improving lives by delivering the full potential of next-generation T-cell immunotherapy to patients with devastating diseases. Integrating a foundational collaboration with the University of Pennsylvania (Penn), with groundbreaking scientific, clinical and manufacturing expertise, and the demonstrated track record of its founders (Carl June, MD; Bruce Levine, PhD; Yangbing Zhao, MD, PhD; Jim Riley, PhD; and Anne Chew, PhD), Tmunity represents a new center of gravity in translational T-cell medicine. Through Penn, the Parker Institute for Cancer Immunotherapy and other collaborations, Tmunity is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T-cell activation and direction in the body, with a focus in cancer and two programs currently in clinic development.

With headquarters in Philadelphia, Tmunity utilizes laboratories and production facilities at Penn, and its own dedicated cGMP manufacturing facility in East Norriton, PA, to pursue process improvement and production scale-up in support of clinical development of its T-cell therapies. For more information, visit www.tmunity.com and connect with us on social media at @TmunityTx and LinkedIn.


Lisa Rivero
Syneos Health
(781) 425-4676